Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,83
KB-0,92
PKN73,773,81,99
Msft284,83284,850,00
Nokia5,2715,2771,64
IBM143,961441,82
Daimler AG75,7875,79-0,86
PFE44,844,811,90
03.08.2021 17:15:54
Indexy online
AD Index online
select
AD Index online
 

  • 02.08.2021
Kazia Therape Rg (Australian)
Závěr k 2.8.2021 Změna (%) Změna (AUD) Objem obchodů (AUD)
1,24 0,00 0,00 -
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 03.08.2021
Popis společnosti
Obecné informace
Název společnostiKazia Therapeutics Ltd
TickerKZA
Kmenové akcie:Fully Paid Ord. Shrs
RICKZA.AX
ISINAU000000KZA9
Poslední známé roční výsledky30.06.2020
Poslední známé čtvrtletní výsledky31.12.2020
Počet zaměstnanců k 30.06.2014 12
Akcie v oběhu k 31.12.2020 126 166 264
MěnaAUD
Kontaktní informace
UliceL 5 20 George St, Hornsby
MěstoSYDNEY
PSČ2077
ZeměAustralia
Kontatní osoba 
Funkce kontaktní osoby 
Telefon61 298 780 088
Fax61294760388

Business Summary: Kazia Therapeutics Limited, formerly Novogen Limited, is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. It has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications. The Company's product candidates include Cantrixil (TRX-E-002-1), Anisina (ATM-3507) and Trilexium (TRX-E-009-1). The Company's target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma. Cantrixil is the lead development candidate arising from its SBP technology. Anisina is an approach to chemotherapy that targets the cancer cells' actin cytoskeleton. Trilexium (TRX-E-009-1) is its second lead SBP drug candidate.
Financial Summary: BRIEF: For the six months ended 31 December 2020, KaziaTherapeutics Ltd revenues decreased 5% to A$31K. Net lossincreased 8% to A$6.4M. Revenues reflect a decrease indemand for the Company's products and services due tounfavorable market conditions. Higher net loss reflectsGeneral and administrative expense increase of 54% toA$3.6M (expense), Research & Development rebate decrease of100% to A$1K (income).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Biotechnology & Medical Research (NEC)
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICS2007Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
NAICS2007Pharmaceutical Preparation Mfg
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Pharmaceutical Preparation Manufacturing
SICCommercial Physical Research
SICPharmaceutical Preparations



  • Poslední aktualizace: 03.08.2021
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chief Executive Officer, Executive DirectorJames Garner4305.02.201605.02.2016
Chief Medical OfficerGordon Hirsch-29.08.201629.08.2016
Clinical & Regulatory Affairs ManagerLilischkis Kimberley-
Chief Business OfficerPeng Leong-29.08.201629.08.2016
Program Director - Degenerative DiseasesStephen Palmer-01.01.2014
Director - ATM ProgramJustine Stehn-03.02.201403.02.2014
Interim Company SecretaryKate Hill-09.09.201609.09.2016